An internationally recognized expert in the mechanisms of neurodegenerative diseases, Dr. Dale Bredesen and his laboratory group have published over 240 scientific papers, including the first descriptions of the reversal of cognitive decline in patients with Alzheimer’s disease and two successful clinical trials, leading to the discoveries that today underlie the ReCODE Protocol™.

 

Dr. Bredesen earned his undergraduate degree from Caltech, his M.D. from Duke University School of Medicine, and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF), before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as the founding President and CEO.

 

Dr. Bredesen’s research explores previously uncharted territory in explaining the mechanisms underlying neurodegenerative diseases such as Alzheimer’s disease, and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkable early results. Dr. Bredesen included many of his findings and research into the 2017 New York Times bestseller, The End of Alzheimer’s.

 

His most recent book, The Ageless Brain, presents a revolutionary new approach to preventing the onset of neurodegenerative disease and creating sustained brain health.